ROW Rights, page-145

I don't know how much more clear the company could be to their direction. 
They've done the first deal to get trof thru Phase III for Retts  & this has left them with enough cash to progress FX, along with 2591.
All this governed by the two principles of speed to market and maximizing shareholder value.

The only other form of direction is coming from pure speculation on these forums of take overs / further deals etc. 

From what the company has communicated - its full steam ahead on getting other applications / candidates to market. They've done the first deal - done the hard yards and we as investors have done the hard yards.


IF you were neu - you would want to wait until pIII data to the pimp out ROW. That would make sense, so I get that the triggering of first right doesn't seem to fit any logical explanation, apart from either there is a deal tabled from global pharma for ROW / Acadia have put together a package that is attractive enough to take it now, vs waiting until results.

Until this is known the companies direction has always been to take this the whole value - speed to market for patients & maximizing value for shareholders. 

If Acadia has a deal that satisfy those two criteria - then this could perhaps change the companies direction, however until then its as previously clearly stated.